The mission of Alderaan Biotechnology is to develop novel therapies to treat cancer by targeting cells from the immune system.
Alderaan Biotechnology programs are related to the elimination of Regulatory T cells and to the hyper activation of Natural Killer cells in the tumor microenvironment.
The company programs are based on the research of its two founding scientists on the use of monoclonal antibodies targeting immune cells to treat cancers. The objective of Alderaan Biotechnology is to develop new antibodies targeting NK cells through CD160-TM and Treg cells through CD25, with oncology as the sole indication focus.
Treg depletion using CD25-specific, IL2 and effector T-cell sparing antibodies
Alderaan Biotechnology raises € 18.5 million in the frameworkhttps://alderaan.mlcreationsteam.eu/wp-content/uploads/2020/10/shutterstock_459376048-760x475@firstname.lastname@example.org://secure.gravatar.com/avatar/3ded63c4df36b25bfcb780925f3ab03d?s=96&d=mm&r=g
📣 Vos recherches méritent d'être visibles !
Pour que vous puissiez développer vos recherches, nos experts vous aident durant toute la chaine de valorisation.
Contactez-nous pour plus d'information 👉 http://swll.to/4NfHy4
#Biomarqueur #RechercheScientifique #Expert
Enter the username or e-mail you used in your profile. A password reset link will be sent to you by email.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.